指南与共识复苏、休克与脓毒症心脑血管急症

指南移除阿托品与成人院内非可除颤心律心脏骤停生存率的关系

Guideline removal of atropine and survival after adult in-hospital cardiac arrest with a non-shockable rhythm.
指南 / 共识 · Resuscitation · 2019-02-13
一句话结论基于Get With The Guidelines®-复苏注册研究,2010年ACLS指南移除阿托品与院内非可除颤心律心脏骤停生存率变化无显著关联。

该研究利用Get With The Guidelines®-复苏注册数据,纳入2006至2015年间成人院内指数心脏骤停患者,包括20499例非可除颤心律和3968例可除颤心律心脏骤停。采用中断时间序列分析比较2010年指南发布前后生存率变化,并用双重差分法比较非可除颤与可除颤队列,以排除与阿托品无关的指南变更影响。主要终点为出院生存率。结果显示,非可除颤队列与可除颤队列相比,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17;指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26,均无统计学显著差异。次要结局和多项敏感性分析结果相似。结论认为,2010年指南移除阿托品与生存率无显著变化相关。

要点

  • 在20499例非可除颤心律和3968例可除颤心律院内心脏骤停中,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17,无显著差异。
  • 指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26,非可除颤与可除颤队列间无显著差异。
  • 阿托品使用率在指南前非可除颤心律为87%(8653例),指南后降至35%(3643例);可除颤心律由35%(680例)降至16%(320例)。
  • 次要结局(自主循环恢复和良好功能结局)及多项敏感性分析结果与主要终点相似。

适用人群与场景

  • 纳入2006至2015年间成人院内指数心脏骤停患者,包括非可除颤心律20499例和可除颤心律3968例。

研究设计与关键结果

  • 研究类型为基于Get With The Guidelines®-复苏注册的注册研究,纳入20499例非可除颤心律和3968例可除颤心律成人院内心脏骤停患者。
  • 主要终点为出院生存率;采用中断时间序列分析比较指南前后生存率变化,并用双重差分法比较非可除颤与可除颤队列。
  • 非可除颤队列与可除颤队列相比,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17。
  • 指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26。
  • 阿托品使用率:指南前非可除颤心律87%(8653例),指南后35%(3643例);指南前可除颤心律35%(680例),指南后16%(320例)。
  • 次要结局(自主循环恢复和良好功能结局)及多项敏感性分析结果与主要终点相似。

证据类型、等级与局限

  • 证据类型:基于Get With The Guidelines®-复苏注册的注册研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: To determine whether the removal of atropine from the 2010 ACLS guidelines for non-shockable cardiac arrests was associated with a change in survival.

METHODS: Using the Get With The Guidelines®-Resuscitation registry, we included adults with an index in-hospital cardiac arrest between 2006 and 2015. The primary outcome was survival to hospital discharge. Secondary outcomes included return of spontaneous circulation and favorable functional outcome. An interrupted time-series analysis was used to compare survival before (pre-guidelines) and after (post-guidelines) introduction of the 2010 guidelines. A difference-in-difference approach was used to compare the interrupted time-series results between the non-shockable and shockable cohorts to account for guideline changes unrelated to atropine.

RESULTS: We included 20,499 non-shockable and 3968 shockable cardiac arrests. Patient characteristics were similar between the pre-guidelines and post-guidelines period. Atropine was used for 8653 (87%) non-shockable and 680 (35%) shockable cardiac arrests in the pre-guidelines period and 3643 (35%) non-shockable and 320 (16%) shockable cardiac arrests in the post-guidelines period. The change over time in survival from the pre-guidelines to the post-guidelines period was not significantly different for the non-shockable compared to the shockable cohort (risk difference: 2.0% [95%CI: -0.8, 4.8] per year, p = 0.17). The immediate change in survival after introducing the guidelines was also not different between the cohorts (risk difference: 3.5% [95%CI: -2.6, 9.7], p = 0.26). Results were similar for the secondary outcomes and in multiple sensitivity analyses.

CONCLUSIONS: The removal of atropine from the 2010 guidelines was not associated with a significant change in survival.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Holmberg MJ, Moskowitz A, Wiberg S, et al. Guideline removal of atropine and survival after adult in-hospital cardiac arrest with a non-shockable rhythm. Resuscitation. 2019. PMID: 30771452. doi:10.1016/j.resuscitation.2019.02.002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。